Andreas Roemer

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

Manfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano et al. · European Journal of Cancer · 2010 · 185 citations

Medicine, Immunology, Oncology +12

The ratio of prostate‐specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL

Carsten Stephan, Greta Stroebel, Marc Heinau et al. · Cancer · 2005 · 67 citations · Full text

Medicine, Oncology, Urology +17

Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome

Andreas Roemer, Lutz Schwettmann, Monika Jung et al. · Oncology Reports · 2004 · 55 citations

Medicine, Molecular Biology, Oncology +11

THE MEMBRANE PROTEASES ADAMS AND HEPSIN ARE DIFFERENTIALLY EXPRESSED IN RENAL CELL CARCINOMA. ARE THEY POTENTIAL TUMOR MARKERS?

Andreas Roemer, Lutz Schwettmann, Monika Jung et al. · The Journal of Urology · 2004 · 53 citations

Medicine, Oncology, Pathology +14